Inhibition of Streptococcus pneumoniae adherence to human epithelial cells in vitro by the probiotic Lactobacillus rhamnosus GG

BMC Research Notes

Catherine Satzke¹  Paul V Licciardi⁶  Roy M Robins-Browne¹  Mimi LK Tang³  E Kim Mulholland⁴  Eileen M Dunne⁵  Zheng Quan Toh⁶  Sook-San Wong² 

[1] Department of Microbiology and Immunology, The University of Melbourne, Parkville, VIC, Australia;Present address: St. Jude Children’s Research Hospital, Memphis, TN, USA;Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia;Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia;Pneumococcal Research, Murdoch Childrens Research Institute, Royal Children’s Hospital, Parkville, VIC, Australia;Allergy and Immune Disorders, Murdoch Childrens Research Institute, Royal Children’s Hospital, Parkville, VIC, Australia

关键词: in vitro model;    Colonization;    Pneumococci;    LGG;    Probiotic;   

Others  :  1143019
DOI  :  10.1186/1756-0500-6-135

 received in 2012-11-26, accepted in 2013-04-01,  发布年份 2013

【 摘 要 】

Background

Colonization of the nasopharynx by Streptococcus pneumoniae is considered a prerequisite for pneumococcal infections such as pneumonia and otitis media. Probiotic bacteria can influence disease outcomes through various mechanisms, including inhibition of pathogen colonization. Here, we examine the effect of the probiotic Lactobacillus rhamnosus GG (LGG) on S. pneumoniae colonization of human epithelial cells using an in vitro model. We investigated the effects of LGG administered before, at the same time as, or after the addition of S. pneumoniae on the adherence of four pneumococcal isolates.

Results

LGG significantly inhibited the adherence of all the pneumococcal isolates tested. The magnitude of inhibition varied with LGG dose, time of administration, and the pneumococcal isolate used. Inhibition was most effective when a higher dose of LGG was administered prior to establishment of pneumococcal colonization. Mechanistic studies showed that LGG binds to epithelial cells but does not affect pneumococcal growth or viability. Administration of LGG did not lead to any significant changes in host cytokine responses.

Conclusions

These findings demonstrate that LGG can inhibit pneumococcal colonization of human epithelial cells in vitro and suggest that probiotics could be used clinically to prevent the establishment of pneumococcal carriage.

【 授权许可】

   
2013 Wong et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T: Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(9693):893-902.
• [2]Gray BM, Converse GM 3rd, Dillon HC Jr: Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 1980, 142(6):923-933.
• [3]Kwambana BA, Barer MR, Bottomley C, Adegbola RA, Antonio M: Early acquisition and high nasopharyngeal co-colonisation by Streptococcus pneumoniae and three respiratory pathogens amongst Gambian new-borns and infants. BMC Infect Dis 2011, 11:175. BioMed Central Full Text
• [4]Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, Muenz LR, O’Brien KL: Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010, 7(10):e1000348.
• [5]Mulholland K, Satzke C: Serotype replacement after pneumococcal vaccination. Lancet 2012, 379(9824):1387.
• [6]FAO/WHO 2001: Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Cordoba, Argentina; 2001. 1 to 4 October
• [7]Macfarlane GT, Cummings JH: Probiotics, infection and immunity. Curr Opin Infect Dis 2002, 15(5):501-506.
• [8]Sullivan A, Nord CE: Probiotics and gastrointestinal diseases. J Intern Med 2005, 257(1):78-92.
• [9]Collado MC, Meriluoto J, Salminen S: Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol 2007, 45(4):454-460.
• [10]Jeon SG, Kayama H, Ueda Y, Takahashi T, Asahara T, Tsuji H, Tsuji NM, Kiyono H, Ma JS, Kusu T: Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog 2012, 8(5):e1002714.
• [11]Anderson RC, Cookson AL, McNabb WC, Kelly WJ, Roy NC: Lactobacillus plantarum DSM 2648 is a potential probiotic that enhances intestinal barrier function. FEMS Microbiol Lett 2010, 309(2):184-192.
• [12]Licciardi PV, Toh ZQ, Dunne E, Wong SS, Mulholland EK, Tang M, Robins-Browne RM, Satzke C: Protecting against pneumococcal disease: critical interactions between probiotics and the airway microbiome. PLoS Pathog 2012, 8(6):e1002652.
• [13]Popova M, Molimard P, Courau S, Crociani J, Dufour C, Le Vacon F, Carton T: Beneficial effects of probiotics in upper respiratory tract infections and their mechanical actions to antagonize pathogens. J Appl Microbiol 2012, 113(6):1305-1318.
• [14]Tanaka A, Seki M, Yamahira S, Noguchi H, Kosai K, Toba M, Morinaga Y, Miyazaki T, Izumikawa K, Kakeya H: Lactobacillus pentosus strain b240 suppresses pneumonia induced by Streptococcus pneumoniae in mice. Lett Appl Microbiol 2011, 53(1):35-43.
• [15]Racedo S, Villena J, Medina M, Aguero G, Rodriguez V, Alvarez S: Lactobacillus casei administration reduces lung injuries in a Streptococcus pneumoniae infection in mice. Microbes Infect 2006, 8(9–10):2359-2366.
• [16]Medina M, Villena J, Salva S, Vintini E, Langella P, Alvarez S: Nasal administration of Lactococcus lactis improves local and systemic immune responses against Streptococcus pneumoniae. Microbiol Immunol 2008, 52(8):399-409.
• [17]Princivalli MS, Paoletti C, Magi G, Palmieri C, Ferrante L, Facinelli B: Lactobacillus rhamnosus GG inhibits invasion of cultured human respiratory cells by prtF1-positive macrolide-resistant group A streptococci. Lett Appl Microbiol 2009, 48(3):368-372.
• [18]Gluck U, Gebbers JO: Ingested probiotics reduce nasal colonization with pathogenic bacteria (Staphylococcus aureus, Streptococcus pneumoniae, and beta-hemolytic streptococci). Am J Clin Nutr 2003, 77(2):517-520.
• [19]Tonnaer EL, Hafmans TG, Van Kuppevelt TH, Sanders EA, Verweij PE, Curfs JH: Involvement of glycosaminoglycans in the attachment of pneumococci to nasopharyngeal epithelial cells. Microbes Infect 2006, 8(2):316-322.
• [20]Ruiz V, Rodriguez-Cerrato V, Huelves L, Del Prado G, Naves P, Ponte C, Soriano F: Adherence of Streptococcus pneumoniae to polystyrene plates and epithelial cells and the antiadhesive potential of albumin and xylitol. Pediatr Res 2011, 69(1):23-27.
• [21]de Leeuw E, Li X, Lu W: Binding characteristics of the Lactobacillus brevis ATCC 8287 surface layer to extracellular matrix proteins. FEMS Microbiol Lett 2006, 260(2):210-215.
• [22]Lorca G, Torino MI, Font de Valdez G, Ljungh AA: Lactobacilli express cell surface proteins which mediate binding of immobilized collagen and fibronectin. FEMS Microbiol Lett 2002, 206(1):31-37.
• [23]Yamaguchi M, Terao Y, Mori Y, Hamada S, Kawabata S: PfbA, a novel plasmin- and fibronectin-binding protein of Streptococcus pneumoniae, contributes to fibronectin-dependent adhesion and antiphagocytosis. J Biol Chem 2008, 283(52):36272-36279.
• [24]Hermans PW, Adrian PV, Albert C, Estevao S, Hoogenboezem T, Luijendijk IH, Kamphausen T, Hammerschmidt S: The streptococcal lipoprotein rotamase A (SlrA) is a functional peptidyl-prolyl isomerase involved in pneumococcal colonization. J Biol Chem 2006, 281(2):968-976.
• [25]Spinler JK, Taweechotipatr M, Rognerud CL, Ou CN, Tumwasorn S, Versalovic J: Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe 2008, 14(3):166-171.
• [26]Wescombe PA, Heng NC, Burton JP, Chilcott CN, Tagg JR: Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics. Future Microbiol 2009, 4(7):819-835.
• [27]Bergeron Y, Ouellet N, Deslauriers AM, Simard M, Olivier M, Bergeron MG: Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice. Infect Immun 1998, 66(3):912-922.
• [28]Xu F, Droemann D, Rupp J, Shen H, Wu X, Goldmann T, Hippenstiel S, Zabel P, Dalhoff K: Modulation of the inflammatory response to Streptococcus pneumoniae in a model of acute lung tissue infection. Am J Respr Cell Mol Biol 2008, 39(5):522-529.
• [29]Heikkinen T, Ghaffar F, Okorodudu AO, Chonmaitree T: Serum interleukin-6 in bacterial and nonbacterial acute otitis media. Pediatr 1998, 102(2 Pt 1):296-299.
• [30]Schmeck B, Moog K, Zahlten J, van Laak V, N’Guessan PD, Opitz B, Rosseau S, Suttorp N, Hippenstiel S: Streptococcus pneumoniae induced c-Jun-N-terminal kinase- and AP-1 -dependent IL-8 release by lung epithelial BEAS-2B cells. Respir Res 2006, 7:98. BioMed Central Full Text
• [31]Zhang L, Xu YQ, Liu HY, Lai T, Ma JL, Wang JF, Zhu YH: Evaluation of Lactobacillus rhamnosus GG using an Escherichia coli K88 model of piglet diarrhoea: Effects on diarrhoea incidence, faecal microflora and immune responses. Vet Microbiol 2010, 141(1–2):142-148.
• [32]Liu F, Li G, Wen K, Bui T, Cao D, Zhang Y, Yuan L: Porcine small intestinal epithelial cell line (IPEC-J2) of rotavirus infection as a new model for the study of innate immune responses to rotaviruses and probiotics. Viral Immunol 2010, 23(2):135-149.
• [33]Nandakumar NS, Pugazhendhi S, Madhu Mohan K, Jayakanthan K, Ramakrishna BS: Effect of Vibrio cholerae on chemokine gene expression in HT29 cells and its modulation by Lactobacillus GG. Scand J Immunol 2009, 69(3):181-187.
• [34]Lopez M, Li N, Kataria J, Russell M, Neu J: Live and ultraviolet-inactivated Lactobacillus rhamnosus GG decrease flagellin-induced interleukin-8 production in Caco-2 cells. J Nutr 2008, 138(11):2264-2268.
• [35]Marriott HM, Gascoyne KA, Gowda R, Geary I, Nicklin MJ, Iannelli F, Pozzi G, Mitchell TJ, Whyte MK, Sabroe I: Interleukin-1beta regulates CXCL8 release and influences disease outcome in response to Streptococcus pneumoniae, defining intercellular cooperation between pulmonary epithelial cells and macrophages. Infect Immun 2012, 80(3):1140-1149.
• [36]Lortat-Jacob H, Grosdidier A, Imberty A: Structural diversity of heparan sulfate binding domains in chemokines. Proc Natl Acad Sci USA 2002, 99(3):1229-1234.
• [37]Webb LM, Ehrengruber MU, Clark-Lewis I, Baggiolini M, Rot A: Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci USA 1993, 90(15):7158-7162.
• [38]Rautava S, Salminen S, Isolauri E: Specific probiotics in reducing the risk of acute infections in infancy–a randomised, double-blind, placebo-controlled study. Br J Nutr 2009, 101(11):1722-1726.
• [39]Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, Kuitunen M: Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatr 2008, 122(1):8-12.
• [40]Hojsak I, Abdovic S, Szajewska H, Milosevic M, Krznaric Z, Kolacek S: Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatr 2010, 125(5):e1171-1177.
• [41]Hojsak I, Snovak N, Abdovic S, Szajewska H, Misak Z, Kolacek S: Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin Nutr 2010, 29(3):312-316.
• [42]Hatakka K, Blomgren K, Pohjavuori S, Kaijalainen T, Poussa T, Leinonen M, Korpela R, Pitkaranta A: Treatment of acute otitis media with probiotics in otitis-prone children-a double-blind, placebo-controlled randomised study. Clin Nutr 2007, 26(3):314-321.
• [43]Skovbjerg S, Roos K, Holm SE, Grahn Hakansson E, Nowrouzian F, Ivarsson M, Adlerberth I, Wold AE: Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. Arch Dis Child 2009, 94(2):92-98.
• [44]Wells JM: Immunomodulatory mechanisms of lactobacilli. Microb Cell Fact 2011, 10(Suppl 1):S17. BioMed Central Full Text
• [45]Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T: Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 1995, 13(3):310-312.
• [46]Walls T, Power D, Tagg J: Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media? J Med Microbiol 2003, 52(Pt 9):829-833.